DiaSorin S.p.A. is an Italy‐based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over‐the‐counter (OTC) securities under the symbol DSRLF.
At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples. Its product range spans infectious disease testing, endocrinology, oncology markers, allergy panels and autoimmune disease assays. DiaSorin complements this reagent offering with proprietary analyzers and automation solutions designed to streamline laboratory workflows and deliver rapid, reliable results.
Originating as a diagnostics division of Sorin Biomedica in 1968, the company was spun off as DiaSorin in 2003 and completed its initial public offering on the Milan exchange in 2007. Since then, DiaSorin has expanded through targeted acquisitions and the establishment of regional subsidiaries, building a presence across Europe, North and Latin America, Asia Pacific and the Middle East. The company maintains research and development centers in Italy, the United States and other key markets to drive innovation in molecular and immunodiagnostic technologies.
Under the leadership of Chief Executive Officer Carlo Rosa, DiaSorin continues to invest in assay development and digital connectivity for laboratory systems. Its global network encompasses direct operations in more than 30 countries and partnerships with distributors in over 130 territories, supporting both centralized and point‐of‐care testing environments.
AI Generated. May Contain Errors.
